Navigation Links
BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

chievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being rece
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
2. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
3. BioCryst to Release Third Quarter 2007 Financial Results on Thursday, November 8, 2007
4. LCA-Vision to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
5. NMB's Fans and Blowers to be Represented in Canada by CST-Arwin
6. The Ensign Group to Present at the Oppenheimer 19th Annual Healthcare Conference
7. Satellite Healthcare Will Present at the American Society of Nephrology's Renal Week – Booth 527 : November 4-9, 2008
8. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
9. Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens
10. Dynavax to Report Third Quarter 2008 Financial Results : -- To Present at Oppenheimer's Healthcare Conference --
11. Robbins & Myers to Present at Sidoti & Company Investor Conference on November 10, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
(Date:4/17/2014)... 94 per cent of Canadians surveyed said they would ... a specific number of genetic conditions, only 80 per ... screening that would sequence their newborns, genomes.,Most newborns in ... first day or two of life in which a ... and tested for about five to 54 conditions, depending ...
(Date:4/16/2014)... the marvel of the embryo. It begins as a glob ... multiply to become the cells of our lungs, muscles, nerves ... Now, in a feat of reverse tissue engineering, Stanford University ... allows embryonic cells to proliferate and transform into all of ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3
... lead to treatment improvements remains unclear , , MONDAY, Feb. ... effects of genetics on blood pressure in humans has ... salt in the body with high blood pressure, a ... "There have been hundreds of genes and gene variants ...
... Feb. 16 The Healthcare Group at Frost & ... Presentation on the,European Cardiac Rhythm Management Market to be ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ... is the leading cause of premature death on a,global ...
... dc fan is ideally suited for PC, servers, telecommunications and networking ... ... -- NMB Technologies Corporation, a Minebea Company, introduced today a new ... offer a higher quality solution for the telecommunication and server industry., ...
... Psychoanalytic Association expresses its deep gratitude to members of ... for mental health information in the health IT implementation ... At a time when the confidence of Americans to ... deeply shaken it is even more important to preserve ...
... rehabs - Mountainside Drug Rehab Center - the pioneer in the ... curriculum that has been replicated by dozens of high-cost drug rehabs. ... ... The economy has been under extraordinary stress, and like most other ...
... DaVita Inc., a leading provider of kidney care services ... kidney failure, today announces a webblog called Kidney Diet ... chronic kidney disease find kidney-friendly recipes and news articles ... DaVita(R) dieticians posted menus and other ideas on what ...
Cached Medicine News:Health News:Genes That Control Body's Salt Levels Are Identified 2Health News:Genes That Control Body's Salt Levels Are Identified 3Health News:Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared? 2Health News:Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared? 3Health News:New Fixed Blade Axial dc Fan From NMB 2Health News:Psychoanalysts Laud Members of Congress for Inclusion of Privacy Protections in Stimulus Bill 2Health News:Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA 2Health News:DaVita.com Kidney Blog Helps Kidney Patients Find Fun Ways to Celebrate Holidays and Tips for Eating Healthy 2Health News:DaVita.com Kidney Blog Helps Kidney Patients Find Fun Ways to Celebrate Holidays and Tips for Eating Healthy 3
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... CVS Caremark Corporation (NYSE: CVS ) today ... dividend of $0.125 (12.5 cents) per share on the Common ... of record on July 22, 2011. (Logo: ... CVS Caremark is the largest pharmacy health care provider ...
... Reportlinker.com announces that a new market ... Growth Hormone Deficiency Global ... http://www.reportlinker.com/p0567405/Growth-Hormone-Deficiency-Global-Clinical-Trials-Review-Q2-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development Growth ... 2011 Summary ...
Cached Medicine Technology:Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 2Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 3Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 4Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 5Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 6Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 7Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 8Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 9
... is a rapid, real-time thermal cycler used ... By automating much of the testing process, ... it is the fastest, easiest to use, ... market. The SmartCycler delivers highly accurate and ...
... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
... Real-Time PCR System gives you advanced, ... budget sensitivity. , , Four-color detection ... analysis, pathogen quantitation, SNP genotyping, and ... , Powerful, versatile software including ...
... of SYBR Green I or FAM in ... fluorophores in the second channel including ... a multitude of applications such as RT-qPCR ... offers precision thermal control and a temperature ...
Medicine Products: